So comparable to SOC but without the deadly side effects. 2.5b revenue from SOC annually. Big cash runway. I can see Amplia negotiating two licensing deals subject to compelling interim data from these two phase 2 trials towards the end of 2023.
Any upfront payments IMO will go towards accelerating amp886 into the clinic.
11c SP low market cap an low SOI. It’s a steal at these prices in my humble opinion!
So comparable to SOC but without the deadly side effects. 2.5b...
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
